Switch theme
Sign up to access all valuation multiples
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology. It operates as a single segment, which is Development of Radiopharmaceuticals. Geographically, it operates in Australia and the United States.
2010
n/a
LTM Revenue $5.1M
LTM EBITDA -$34.1M
$464M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Clarity Pharmaceuticals has a last 12-month revenue of $5.1M and a last 12-month EBITDA of -$34.1M.
In the most recent fiscal year, Clarity Pharmaceuticals achieved revenue of n/a and an EBITDA of -$35.5M.
Clarity Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Clarity Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$22.8M | -$35.5M | XXX | XXX | XXX |
| EBITDA Margin | NaN% | NaN% | XXX | XXX | XXX |
| Net Profit | -$15.0M | -$15.6M | XXX | XXX | XXX |
| Net Margin | NaN% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 17, 2025, Clarity Pharmaceuticals's stock price is AUD 3 (or $2).
Clarity Pharmaceuticals has current market cap of AUD 845M (or $534M), and EV of AUD 734M (or $464M).
See Clarity Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $464M | $534M | XXX | XXX | XXX | XXX | $-0.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 17, 2025, Clarity Pharmaceuticals has market cap of $534M and EV of $464M.
Clarity Pharmaceuticals's trades at 91.3x LTM EV/Revenue multiple, and -13.6x LTM EBITDA.
Analysts estimate Clarity Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Clarity Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $464M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -12.7x | XXX | XXX | XXX |
| P/E | -17.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -15.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpClarity Pharmaceuticals's NTM/LTM revenue growth is 43%
Clarity Pharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Clarity Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Clarity Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Clarity Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 56% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Clarity Pharmaceuticals acquired XXX companies to date.
Last acquisition by Clarity Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Clarity Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Clarity Pharmaceuticals founded? | Clarity Pharmaceuticals was founded in 2010. |
| Where is Clarity Pharmaceuticals headquartered? | Clarity Pharmaceuticals is headquartered in Australia. |
| Who is the CEO of Clarity Pharmaceuticals? | Clarity Pharmaceuticals's CEO is Ms. Michelle Parker. |
| Is Clarity Pharmaceuticals publicy listed? | Yes, Clarity Pharmaceuticals is a public company listed on ASX. |
| What is the stock symbol of Clarity Pharmaceuticals? | Clarity Pharmaceuticals trades under CU6 ticker. |
| When did Clarity Pharmaceuticals go public? | Clarity Pharmaceuticals went public in 2021. |
| Who are competitors of Clarity Pharmaceuticals? | Similar companies to Clarity Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Clarity Pharmaceuticals? | Clarity Pharmaceuticals's current market cap is $534M |
| What is the current revenue of Clarity Pharmaceuticals? | Clarity Pharmaceuticals's last 12-month revenue is $5.1M. |
| What is the current EBITDA of Clarity Pharmaceuticals? | Clarity Pharmaceuticals's last 12-month EBITDA is -$34.1M. |
| What is the current EV/Revenue multiple of Clarity Pharmaceuticals? | Current revenue multiple of Clarity Pharmaceuticals is 91.3x. |
| What is the current EV/EBITDA multiple of Clarity Pharmaceuticals? | Current EBITDA multiple of Clarity Pharmaceuticals is -13.6x. |
| Is Clarity Pharmaceuticals profitable? | Yes, Clarity Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
